Cost Effectiveness of Memantine in Alzheimers Disease: An Analysis Based on a Probabilistic Markov Model from a UK Perspective

Author： Roy W. Jones

Publisher： Adis International

ISSN： 1170-229X

Source： Drugs & Aging, Vol.21, Iss.9, 2004-01, pp. : 607-620

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost Effectiveness of Memantine in Moderately Severe to Severe Alzheimers Disease: A Markov Model in Finland

By François C.

Clinical Drug Investigation, Vol. 24, Iss. 7, 2004-01 ,pp. : 373-384

Adis International

Access to resources Recommend Favorite

Health Utilities in Alzheimers Disease and Implications for Cost-Effectiveness Analysis

By Neumann Peter J.

PharmacoEconomics, Vol. 23, Iss. 6, 2005-01 ,pp. : 537-541

Adis International

Access to resources Recommend Favorite

A Markov Model of the Cost Effectiveness of Olanzapine Treatment for Agitation and Psychosis in Alzheimer's Disease

By Kirbach Stephanie

Clinical Drug Investigation, Vol. 28, Iss. 5, 2008-01 ,pp. : 291-303

Adis International

Access to resources Recommend Favorite

Evaluation of memantine for the treatment of Alzheimer’s disease

By Ferris Steven H

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 12, 2003-12 ,pp. : 2305-2313

Informa Healthcare

Access to resources Recommend Favorite

Resource Utilisation and Cost Analysis of Memantine in Patients with Moderate to Severe Alzheimer's Disease

By Wimo A.

PharmacoEconomics, Vol. 21, Iss. 5, 2003-01 ,pp. : 327-340

Adis International

Access to resources Recommend Favorite